Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients

INTRODUCTION: The measurement of body composition such as the skeletal muscle index (SMI) has been reported to be useful for predicting prognosis in hepatocellular carcinoma (HCC). In this study, we analyzed skeletal muscle change during sorafenib and lenvatinib therapy and the association between S...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Liver Cancer
Auteurs principaux: Uchikawa, Shinsuke, Kawaoka, Tomokazu, Namba, Maiko, Kodama, Kenichiro, Ohya, Kazuki, Morio, Kei, Nakahara, Takashi, Murakami, Eisuke, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Takahashi, Shoichi, Chayama, Kazuaki, Aikata, Hiroshi
Format: Artigo
Langue:Inglês
Publié: S. Karger AG 2020
Sujets:
Original Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7206610/
https://ncbi.nlm.nih.gov/pubmed/32399429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503829
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires